Showing results (131-140 of 241) with videos related to
Sort By:
Pageof 25
Science Advances|February 20, 2021
Patient-tailored design for selective co-inhibition of leukemic cell subpopulationsAleksandr Ianevski, Jenni Lahtela, Komal K Javarappa, et al.Blood|January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.Molecular Oncology|September 21, 2025
Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemiaJoseph Saad, Rhiannon Newman, Elmira Khabusheva, et al.Journal of Virology|January 15, 2005
Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cellsBlair L Strang, Yasuhiro Takeuchi, Thomas Relander, et al.Bone|January 17, 2012
Murine ameloblasts are immunonegative for Tcirg1, the v-H-ATPase subunit essential for the osteoclast plasma proton pumpAntonius L J J Bronckers, Donacian M Lyaruu, Theodore J Bervoets, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous LeukemiaSieghart Sopper, Satu Mustjoki, Deborah White, et al.Haematologica|October 5, 2014
The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemiaHanna L M Rajala, Thomas Olson, Michael J Clemente, et al.Blood|March 13, 2013
Selective killing of candidate AML stem cells by antibody targeting of IL1RAPMaria Askmyr, Helena Ågerstam, Nils Hansen, et al.Proceedings of the National Academy of Sciences of the United States of America|September 7, 2006
Effective cell and gene therapy in a murine model of Gaucher diseaseIda Berglin Enquist, Eva Nilsson, Andreas Ooka, et al.Leukemia Research|January 18, 2003
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemiaAstrid Gruber, Magnus Björkholm, Lorentz Brinch, et al.Pageof 25